entertainment -WSS

entertainment

author：knowledge 2025-08-19 15:01:39 - browse：52

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play

leisure time

WSS

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Bill would stop addiction treatment from triggering child abuse inquiry

In rare move, senator releases unverified FBI source report alleging Biden bribe

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Analysis of telehealth claims data suggest service duplication

Histogen: Failed biotech offers rare public look inside

explore

entertainment

knowledge

How one medical school became remarkably diverse

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

How one medical school became remarkably diverse

Are infertility treatments 'essential' during the Covid

23andMe had bad news about my health. I wish a person had delivered it

Senate panel eyes new effort on drug shortages

Walensky prepares to leave CDC — and Congress — behind

FDA panel signals lack of confidence in Amgen cancer drug data

Medicare details structure of new drug price negotiation program

How a Boston hospital is priming medical residents to use GPT

leisure time

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Sanders wants to replace patents with prizes for drug inventions

FDA panel signals lack of confidence in Amgen cancer drug data

What to expect at HLTH 2023, the health care industry conference

How a Boston hospital is priming medical residents to use GPT

Physician executives need more than on

Wikipedia

leisure time

focus

hotspot